Figure 1.
HLA-E and EBV LMP-1 variants in patients with IM and asymptomatic EBV-seropositive individuals. (A-D) Distribution of HLA-E variants between control persons (N = 412) (A), asymptomatic EBV-seropositive persons (N = 206) (B), adolescent/adult patients with IM (N = 412) (C), and pediatric patients with IM (N = 166) (D). Fractions represent the relative frequency of HLA-E∗0101/0101, HLA-E∗0101/0103, and HLA-E∗0103/0103 variants. (E-F) LMP-1 peptide variants in adolescent/adult patients with IM (N = 412) (E) and pediatric patients with IM (N = 166) (F). Fractions represent the relative frequency of the LMP-1 peptide GGDPHLPTL, GSDPHLPTL, GGDPHLPPL, GGDPPLPTL, GCDPHLPTL, GIDPHLPTL, GAGPHLPTL, GGDTPLPTL, GDDPHLPTL, GGDPHVPTL, and GTDPHLPTL variants. +The frequency of the HLA-E genotypes was compared with the control cohort by the χ2 test. ++The frequency of the LMP-1 variants was compared with the adolescent/adult cohort with IM by the χ2 test.

HLA-E and EBV LMP-1 variants in patients with IM and asymptomatic EBV-seropositive individuals. (A-D) Distribution of HLA-E variants between control persons (N = 412) (A), asymptomatic EBV-seropositive persons (N = 206) (B), adolescent/adult patients with IM (N = 412) (C), and pediatric patients with IM (N = 166) (D). Fractions represent the relative frequency of HLA-E∗0101/0101, HLA-E∗0101/0103, and HLA-E∗0103/0103 variants. (E-F) LMP-1 peptide variants in adolescent/adult patients with IM (N = 412) (E) and pediatric patients with IM (N = 166) (F). Fractions represent the relative frequency of the LMP-1 peptide GGDPHLPTL, GSDPHLPTL, GGDPHLPPL, GGDPPLPTL, GCDPHLPTL, GIDPHLPTL, GAGPHLPTL, GGDTPLPTL, GDDPHLPTL, GGDPHVPTL, and GTDPHLPTL variants. +The frequency of the HLA-E genotypes was compared with the control cohort by the χ2 test. ++The frequency of the LMP-1 variants was compared with the adolescent/adult cohort with IM by the χ2 test.

Close Modal

or Create an Account

Close Modal
Close Modal